regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Biden was consistently ranked one of the least wealthy members of the Senate, which he attributed to having been elected young. Feeling that less-wealthy public officials may be tempted to accept contributions in exchange for political favors, he proposed campaign finance reform measures during his first term. While a senator, Biden was viewed as being close to the credit card company MBNA, a major contributor to his campaigns since 1989, sometimes being called the "senator from MBNA". As of November 2009, Biden's net worth was $27,012. By November 2020, the Bidens were worth $9 million, largely due to sales of Biden's books and speaking fees after his vice presidency. Political columnist David S. Broder wrote that Biden has grown over time: "He responds to real people—that's been consistent throughout. And his ability to understand himself and deal with other politicians has gotten much, much better." Journalist James Traub has written that "Biden is the kind of fundamentally happy person who can be as generous toward others as he is to himself". Particularly since the 2015 death of his elder son Beau, Biden has been noted for his empathetic nature and ability to communicate about grief. Journalist and TV anchor Wolf Blitzer has called Biden loquacious; journalist Mark Bowden has said that he is famous for "talking too much", leaning in close "like an old pal with something urgent to tell you". He often deviates from prepared remarks, and sometimes "puts his foot in his mouth". Biden has a reputation for being prone to gaffes.
And that's the S&D Group." One of the assistants whose flats were searched (Giuseppe Meroni) works for the EPP member Lara Comi, and the EPP member Maria Spyraki was later also put under investigation by the European Public Prosecutor's Office (EPPO). The S&D Group commissioned an inquiry conducted from March to June 2023 by three independent experts: former MEP Richard Corbett, auditor and governance expert Jean-Pierre Garitte, and expert in economic criminal law Silvina Bacigalupo. They presented their initial report to the Group in July. It warned of a heightened risk of geostrategic interference and geostrategic corruption and warned that the EU institutions need to strengthen their resilience by updating their rules and procedures. It pointed out that the existing regulatory framework laying down ethical requirements for MEPs and staff is distributed over at least 27 different documents at various levels of the legal hierarchy, from treaty-level provisions to EU legislation, inter-institutional agreements, parliamentary rules of procedure, the MEP code of conduct and a range of decisions by the Parliament, its Bureau, the Conference of Presidents and the Secretary General. The report identified some 50 shortcomings in them, from gaps to contradictions, weak wording, unclear obligations and inadequate enforcement. This part of the report fed into the subsequent revision of the European Parliament's Rules of Procedure and the Code of Conduct for Members (see below) adopted in September 2023.
Amifostine is an organic thiophosphate prodrug which is hydrolysed in vivo by alkaline phosphatase to the active cytoprotective thiol metabolite, WR-1065. The selective protection of non-malignant tissues is believed to be due to higher alkaline phosphatase activity, higher pH, and vascular permeation of normal tissues. Amifostine can be administered intravenously or subcutaneously after reconstitution with normal saline. Infusions lasting less than 15 minutes decrease the risk of adverse effects. The patient should be well-hydrated prior to administration.
According to Democracy Now!, "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug." The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval. In 2007, Pfizer published a Statement of Defense letter, claiming that Trozan was safely tested in five thousand patients prior to the Nigerian children clinical trial, and mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics. They claim that the effects suffered by the victims were due to meningitis and not Trovan. Pfizer states that its actions did not violate any law, as there was no law in Nigeria that requires ethical committee approval prior to conducting a clinical trial. However, the drug was never tested in children before. Pfizer claims that no unusual side effects, unrelated to meningitis, were observed after four weeks in the Nigerian children clinical study, though an investigation by The Washington Post revealed that one of the children continued to have the drug administered to them until their death despite their condition worsening, which violated ethical guidelines.
Sources: en.wikipedia.org
West Yorkshire is ethnically diverse, hosting large populations of multiple ethnic minority groups. Most notably, the city of Bradford is well known for its large concentration of British Pakistanis, the highest by percentage in the country. Leeds and Kirklees also have large British Pakistani populations. Kirklees also hosts a large population of British Indians. West Yorkshire is home to a large Eastern European population, particularly British Poles. Ethnic minorities totalled to over 21% of West Yorkshire's population in 2011.
== Related compounds == N-Methyliminodiacetic acid (MIDA), the N-methyl derivative of IDA Imidodiacetic acid, the amino diacetic acid N-(2-Carboxyethyl)iminodiacetic acid, a more biodegradable analogue of NTA N-hydroxyiminodiacetic acid (HIDA), HON(CH2CO2H)2 (registry number = 87339-38-6) See HIDA scan.
There were proposals to extend this corridor 7 miles to Chapel Hill with light rail technology. However, in 2006 Triangle Transit deferred implementation indefinitely when the Federal Transit Administration declined to fund the program due to low ridership projections. The region's two metropolitan planning organizations appointed a group of local citizens in 2007 to reexamine options for future transit development in light of Triangle Transit's problems. The Special Transit Advisory Commission (STAC) retained many of the provisions of Triangle Transit's original plan but recommended adding new bus services and raising additional revenues by adding a new local half-cent sales tax to fund the project. Greyhound Lines provides an inter-city bus service to Durham, Charlotte, Richmond, Washington, D.C., Atlanta, and other cities.
Sources: en.wikipedia.org
The Act was last amended in the year 2009 and all the financial institutes are following this act. Till today there are 26 circulars issued by Bangladesh Bank under this act. To prevent money laundering, a banker must do the following:
== External links == Sophora flavescens Ait. Ya Ling, Jian; Ying Zhang, Guo; Jie Cui, Zhao; Kai Zhang, Chang (2007). "Supercritical fluid extraction of quinolizidine alkaloids from Sophora flavescens Ait. and purification by high-speed counter-current chromatography" (PDF). Journal of Chromatography A. 1145 (1–2): 123–127. doi:10.1016/j.chroma.2007.01.080. PMID 17289059. Krishna, Panthati Murali; Knv, Rao; S, Sandhya; Banji, David (2012). "A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae". Revista Brasileira de Farmacognosia. 22 (5): 1145–1154. doi:10.1590/S0102-695X2012005000043.
deoxyribonucleic acid (DNA) A polymeric nucleic acid molecule composed of a series of covalently linked deoxyribonucleotides, each of which incorporates one of four nucleobases: adenine (A), guanine (G), cytosine (C), and thymine (T). DNA is most often found in double-stranded form, which consists of two complementary, antiparallel nucleotide chains in which each of the nucleobases on each individual strand is paired via hydrogen bonding with one on the opposite strand; this structure commonly assumes the shape of a double helix. DNA can also exist in single-stranded form. By storing and encoding genetic information in the sequence of these nucleobases, DNA serves as the universal molecular basis of biological inheritance and the fundamental template from which all proteins, cells, and living organisms are constructed.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.